Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: A possible role for 14-3-3 theta/tau and tBID?

Journal of Proteomics

Volumn 75, Issue 4, 2012, Pages 1276-1283

  Hodgkinson, Victoria C ^a   ELFadl, Dalia ^a,b   Agarwal, Vijay ^a,b,c   Garimella, Veerabhadram ^a,b   Russell, Charlotte ^a   Long, Ervine D ^b   Fox, John N ^b   McManus, Penelope L ^b   Mahapatra, Tapan K ^b   Kneeshaw, Peter J ^b   Drew, Philip J ^a,b,c   Lind, Michael J ^a,b,c   Cawkwell, Lynn ^a,c  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Antibody microarray; Biomarkers; Breast cancer chemotherapy; Neoadjuvant proteomics

Indexed keywords

ANTHRACYCLINE; ANTIBODY; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MYELOID DIFFERENTIATION FACTOR 88; PININ PROTEIN; PROTEIN 14 3 3; PROTEIN BCL XL; PROTEIN RIP; TAU PROTEIN; TBID PROTEIN; UNCLASSIFIED DRUG; ZYXIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER TISSUE; CLINICAL EVALUATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; SAMPLING; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VALIDATION STUDY;

14-3-3 PROTEINS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; TAXOIDS;

EID: 84855877854     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.11.005     Document Type: Article

References (34)

1. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
2. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
3. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-8423.
4. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68.
5. Bhargava R., Beriwal S., Dabbs D.J., Ozbek U., Soran A., Johnson R.R., et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer 2010, 116:1431-1439.
6. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
7. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334.
8. Colleoni M., Viale G., Zahrieh D., Bottiglieri L., Gelber R.D., Veronesi P., et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 2008, 19:465-472.
9. von Minckwitz G., Sinn H.-P., Raab G., Loibl S., Blohmer J.-U., Eidtmann H., et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008, 10:R30.
10. Colleoni M., Bagnardi V., Rotmensz N., Gelber R., Viale G., Pruneri G., et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 2009, 116:359-369.
11. Darb-Esfahani S., Loibl S., Muller B., Roller M., Denkert C., Komor M., et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 2009, 11:R69.
12. Kim S.I., Sohn J., Koo J.S., Park S.H., Park H.S., Park B.W. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology 2010, 79:324-330.
13. Huober J., von Minckwitz G., Denkert C., Tesch H., Weiss E., Zahm D., et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010, 124:133-140.
14. Precht L.M., Lowe K.A., Atwood M., Beatty J.D. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 2010, 16:362-368.
15. Straver M., Rutgers E., Rodenhuis S., Linn S., Loo C., Wesseling J., et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 2010, 17:2411-2418.
16. Naoi Y., Kishi K., Tanei T., Tsunashima R., Tominaga N., Baba Y., et al. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Cancer 2011, 117:3682-3690.
17. Lin Y., Lin S., Watson M., Trinkaus K., Kuo S., Naughton M., et al. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2010, 123:691-699.
18. Straver M., Glas A., Hannemann J., Wesseling J., van de Vijver M., Rutgers E., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119:551-558.
19. Hodgkinson V.C., Eagle G.L., Drew P.J., Lind M.J., Cawkwell L. Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Lett 2010, 294:13-24.
20. Chuthapisith S., Layfield R., Kerr I., Hughes C., Eremin O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 2007, 30:1545-1551.
21. Liu Y., Liu H., Han B., Zhang J.-T. Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 2006, 66:3248-3255.
22. Smith L., Watson M.B., O'Kane S.L., Drew P.J., Lind M.J., Cawkwell L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther 2006, 5:2115-2120.
23. Kopf E., Zharhary D. Antibody arrays - an emerging tool in cancer proteomics. Int J Biochem Cell Biol 2007, 39:1305-1317.
24. Kopf E., Shnitzer D., Zharhary D. Panorama™ Ab microarray cell signaling kit: a unique tool for protein expression analysis. Proteomics 2005, 5:2412-2416.
25. Hodgkinson V.C., Elfadl D., Drew P.J., Lind M.J., Cawkwell L. Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. J Proteomics 2011, 74:698-703.
26. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
27. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
28. Garimella V., Watson M., Cairns H., Chatuverdi A., Drew P., Hubbard A., et al. Assessment of apoptotic markers as predictors of response to neoadjuvant FEC chemotherapy in locally advanced breast cancer. Cancer Ther 2007, 5:239-242.
29. Cawkwell L., Gray S., Murgatroyd H., Sutherland F., Haine L., Longfellow M., et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999, 45:409-415.
30. Pommier Y., Sordet O., Antony S., Hayward R.L., Kohn K.W. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004, 23:2934-2949.
31. Tzivion G., Gupta V.S., Kaplun L., Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006, 16:203-213.
32. Masters S.C., Subramanian R.R., Truong A., Yang H., Fujii K., Zhang H., et al. Survival-promoting functions of 14-3-3 proteins. Biochem Soc Trans 2002, 30:360-365.
33. Wang B., Liu K., Lin H.-Y., Bellam N., Ling S., Lin W.-C. 14-3-3{tau} regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Mol Cell Biol 2010, 30:1508-1527.
34. Vazquez A., Grochola L., Bond E., Levine A., Taubert H., Muller T., et al. Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3 tau and CD44 that affect sarcoma incidence and survival. Mol Cell Pathobiol 2010, 70:172-180.